



Numiera Therapeutics

STALLING THE ENGINES OF CANCER CELLS

Corporate Overview

Q1 2025



Glioblastoma is an aggressive and deadly brain cancer


10,000 - 15,000 newly-diagnosed cases each year in the United States

Glioblastoma is a high-grade malignancy

- Median survival of ~12 months with standard therapies, comprising surgery and radiotherapy
- The addition of the chemotherapy drug temozolomide increases median survival by only ~2 months

Only one therapy has reached market and benefited patients in 50 years

New treatment options are desperately needed to extend survival time






The metabolism of fatty acids is critical for glioblastoma cells

Society for Neuro Oncology Translational Research Award 2016


- Human glioma cells express the necessary enzymes to make energy via fatty acid metabolism
- High expression of these enzymes in the tumor directly correlates with poor disease prognosis
- Blocking this metabolic pathway (with etomoxir) slows the growth of glioma cells



Human glioma cells

Preclinical Data with Lead Small Molecule

CONTROL 75 days post-implantation of glioma cells, significant tumor growth is observed in mice under MRI.



TREATED 75 days post-implantation of glioma cells, no tumor growth is observed in mice under MRI.






This metabolic vulnerability presents a druggable target

Building on 20+ years of laboratory research and drug development

Cancer cells require energy to support malignant growth and recover from chemotherapy

Our drug blocks the rate-limiting step in fatty acid metabolism (CPT1)

Chemotherapy damages DNA



Standard of Care: Temozolomide

Drug blocks energy production needed for repair and replication



Lead Small Molecule: Etomoxir




Key competitive advantages

Small molecule compound targeting CPT-1



Specific targeting of cancer cells



No viable compensatory mechanism



Add-on to current standard of care



Well-established safety and pharmacology



Simple and low-cost manufacture

- ✓ *Independently-replicated preclinical efficacy data in our primary disease indication*
- ✓ *Full CMC-pharmacology-toxicology dataset for our lead candidate drug*
- ✓ *Highly motivated clinical partners and patient population*




Competitive landscape for glioblastoma indication

Orphan drug designation provides 7 years of post-approval market exclusivity

Primary Competitor: Temozolomide (Temodar) gives glioblastoma patients 2-3 extra months, and is currently the standard of care chemotherapy

Bevacizumab (Avastin) is effective at treating colorectal cancer and non-small-cell lung cancer, but not glioblastoma, although it is still often prescribed for that condition

Modifi, a Yale University spinout founded in 2021, has shown preclinical efficacy for a new class of temozolomide analogs to treat glioblastoma



¹ Cancer Research UK; ² STATISTICA; ³ REUTERS..




Market opportunity in multiple cancer indications

Glioblastoma beachhead indication expanding to other oncology indications



- The naturally occurring P479L mutation significantly reduces CPT1 enzyme activity ¹
- This 'arctic variant' is associated with dramatically reduced incidence of various cancers ²
- The CPT1 inhibitor etomoxir slows tumor growth in preclinical animal models of the same cancers

This target may address a total market of **five million cancer patients** diagnosed globally each year



Glioblastoma-related **SOM** opportunity of \$1B+ by anticipated market approval date ³

Brain tumor-related **SAM** opportunity of \$3B+ by anticipated market approval date ⁴


Treatment-resistant cancer **TAM** opportunity of \$50B+ today ⁵

¹ Greenberg et al. Mol Gen Metab 2009; ² Friberg et al. Lancet Oncology 2008; ³ Grand View Research; ⁴ The Insight Partners; ⁵ WHO; TAM, total addressable market; SAM, serviceable addressable market; SOM, serviceable obtainable market; art by Kenojuak Ashevak.



Intellectual property portfolio


Significant opportunity for patent portfolio expansion





Development timeline

Optimized fast-track timeline with significant near-term value-inflection points





Investment opportunity

Venture Capital + \$250K competitively-awarded funds from Colorado's Office of Economic Development (OEDIT)



Planned Use of Funds

Corporate Development

- Expand intellectual property portfolio
- Secure orphan drug designations

Clinical Trials Preparation

- Prepare documents for regulatory agencies
- Coordinate patients and clinical investigators

Moving Forward

- Source support for early-phase clinical trials, primarily through grant funding
- Manufacture drug for clinical trials



Corporate structure

Leadership Team



Izi Stoll, PhD
Co-Founder/CEO



John Nieland, PhD
Product Development




Josh Pan, PhD MBA
Business Development



Karl Nicholls, CPA
Financial Strategy



Gordon Beck, PhD
Corporate Strategy



Sam Bromley-Coolidge
Communications Strategy

Consultant Clinician

Patrick Wen, MD
Director, Center for Neuro Oncology
Dana Farber Cancer Institute

Supporting Organizations



THE WESTERN INSTITUTE FOR ADVANCED STUDY





Thank you



Numiera Therapeutics

STALLING THE ENGINES OF CANCER CELLS

Let's talk more:
partnerships@numiera.com